Q-omics provides the consensus-scored PITX1 profile across patient tissues and cancer cell-line models. PITX1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PITX1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PITX1 RNA expression shows 16,176 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where PITX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PITX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PITX1 survival associations across molecular data types. PITX1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PITX1 RNA expression–survival associations across cancer types. High PITX1 expression shows unfavorable associations in KIRC, ACC, UVM, LUAD, BLCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PITX1 RNA expression.
This table summarizes PITX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PITX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PITX1 shows lower tumor expression in HNSC and BLCA and higher tumor expression in COAD, LUSC, LUAD and LIHC. The COAD box plot shows higher PITX1 RNA expression in tumor versus normal tissue (log2 FC = +2.237, t-test p < 0.001).
This table shows molecular features associated with PITX1 in patient tissues and cancer cell lines. In patient samples, PITX1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PITX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
